. 2022 Mar 10;9:847114. doi: 10.3389/fnut.2022.847114

Table 3.

Baseline-corrected plasma PK parameters for DHA, EPA, ALA, and DPA within 72 h post-dose of LC-ω3-rich canola oil.

		High-dose	Mid-dose	Low-dose	Placebo
DHA	AUC_0−72h (μg*h/mL)	360.60 ± 211.63^a	269.86 ± 233.19^ab	175.57 ± 165.49^b	193.49 ± 207.30^b
	C_max (μg/mL)	21.18 ± 9.51^a	13.14 ± 6.44^b	9.40 ± 5.96^c	6.72 ± 6.23^c
	T_max (hour)	11.38 ± 17.89^a	8.71 ± 12.68^a	15.97 ± 23.12^a	17.82 ± 16.50^a
EPA	AUC_0−72h (μg*h/mL)	78.21 ± 74.62^a	70.50 ± 87.12^a	57.52 ± 85.91^a	52.68 ± 87.00^a
	C_max (μg/mL)	3.47 ± 2.55^a	3.18 ± 2.93^a	3.05 ± 2.77^a	2.87 ± 3.09^a
	T_max (hour)	14.93 ± 17.94^a	15.00 ± 18.65^a	14.08 ± 19.98^a	19.00 ± 21.04^a
ALA	AUC_0−72h (μg*h/mL)	533.07 ± 560.08^a	362.86 ± 279.39^ab	249.61 ± 237.92^b	346.89 ± 379.87^ab
	C_max (μg/mL)	45.55 ± 25.53^a	33.51 ± 16.84^b	19.82 ± 12.08^c	19.70 ± 17.98^c
	T_max (hour)	8.06 ± 10.60^a	8.35 ± 12.07^a	8.38 ± 7.87^a	11.42 ± 8.70^a
DPA	AUC_0−72h (μg*h/mL)	107.25 ± 126.82^a	82.48 ± 94.25^a	67.40 ± 69.29^a	75.70 ± 82.54^a
	C_max (μg/mL)	4.28 ± 3.39^a	3.33 ± 2.65^a	2.80 ± 2.52^a	2.81 ± 2.33^a
	T_max (hour)	18.87 ± 22.57^a	19.67 ± 22.35^a	25.34 ± 24.77^a	23.45 ± 21.49^a

Values are means ± SD. For each parameter, different letters (a,b,c,d) indicates statistically significant differences between groups (P < 0.05); t-test was applied to baseline-corrected AUC_0−72h and C_max, and Mann–Whitney U-test was applied to T_max. For DHA, n = 32, 31, 30, and 28 for high-dose, mid-dose, low-dose, and placebo groups; for EPA, n = 30, 28, 26, and 26 for high-dose, mid-dose, low-dose, and placebo groups; for ALA, n = 32, 31, 32, and 31 for high-dose, mid-dose, low-dose, and placebo groups; for DPA, n = 31, 30, 29, and 29 for high-dose, mid-dose, low-dose, and placebo groups. ALA, alpha-linolenic acid; AUC, area under the curve; C_max, peak concentration; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; PK, pharmacokinetics; T_max, time at which the C_max is observed.